β3肾上腺素受体基因Trp64Arg多态性与中国男性2型糖尿病患者合并高尿酸血症的相关性研究

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (3): 307-311.

β3肾上腺素受体基因Trp64Arg多态性与中国男性2型糖尿病患者合并高尿酸血症的相关性研究

黄琼¹, 张留福², 程雁³, 司力⁴, 魏伟¹

¹安徽医科大学临床药理研究所,抗炎免疫药物教育部重点实验室,合肥 230032,安徽
²安徽医科大学第三附属医院,合肥市第一人民医院神经内科,合肥 230061,安徽
³安徽医科大学第一附属医院儿科,合肥 230022,安徽
⁴安徽医科大学第一附属医院检验科,合肥 230022,安徽

收稿日期:2012-08-20 修回日期:2012-12-03 出版日期:2013-03-26 发布日期:2013-04-02

Effect of β3-adrenergic receptor gene Trp64Arg polymorphism on uric acid levels in a Chinese male type 2 diabetes mellitus population

HUANG Qiong¹, ZHANG Liu-fu², CHENG Yan³, SI Li⁴, WEI Wei¹

¹Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Hefei 230032, Anhui, China
²Department of Neurology, the Third Affiliated Hospital of Anhui Medical University, First People's Hospital in Hefei, Hefei 230061, Anhui, China
³Department of Pediatrics
⁴Clinical Laboratory, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui, China

Received:2012-08-20 Revised:2012-12-03 Online:2013-03-26 Published:2013-04-02
Contact: WEI Wei, correspondence author, male, Ph.D, tutor of Ph.D. student, engaged in antiinflammatory - immunity pharmacology.Tel: 0551-5161209 E-mail: wwei@ahmu.edu.cn
Supported by:
This study was supported by the National Natural Science Foundation of China Grants(81202596), Specialized Research Fund for the Doctoral Program of Higher Education (20113420120006), Grants for Scientific Research of BSKY (XJ201021) from Anhui Medical University, Research Foundation of Anhui Medical University (2011xkj011), Anhui province Nature Science Foundation in University (KJ2012Z158)

摘要/Abstract

摘要： 目的: 探讨中国人群男性2型糖尿病患者中β3肾上腺素受体基因Trp64Arg多态性与高尿酸血症的相关性。方法: 196名高尿酸血症的2型糖尿病患者和196名正常尿酸水平的2型糖尿病患者进行基因分型。检测体重指数、腰臀比、收缩压、舒张压、血尿酸、肌酐、尿素氮、甘油三酯、低密度脂蛋白胆固醇脂、高密度脂蛋白胆固醇脂、空腹血糖和餐后血糖的水平。结果: 高尿酸血症组中,携带不同β3肾上腺素受体Trp64Arg基因型的2型糖尿病患者其尿酸水平有统计学差异,且呈基因剂量效应[CC组(599.53±113.70) vs CT组(529.78±81.10) vs TT组(507.33±74.27), P<0.01]。在该研究中,Trp64Arg TC+CC基因型患者的血尿酸水平亦显著高于TT基因型组[(557.95±99.91) vs (503.47±69.40) μmol/L, P<0.01]。结论: β3肾上腺素受体基因Trp64Arg多态性与2型糖尿病合并高尿酸血症的具有相关性。

关键词: β3肾上腺素受体, 基因多态性, 高尿酸血症, 尿酸, 2型糖尿病, 相关性分析

Abstract: AIM: To investigate the association of β3-adrenergic receptor gene Trp64Arg polymorphism with hyperuricemia in a Chinese male type 2 diabetes mellitus patients population.METHODS: 196 hyperuricemic and 196 normouricemic male subjects were genotyped in this study. Body mass index (BMI), waist to hip ratio (WHR), systolic blood pressure (SBP), diastolic blood pressure (DBP), serum uric acid, urea nitrogen, creatinine, triglyceride, total cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), fasting plasma glucose (FPG), postprandial plasma glucose (PPG) were detected.RESULTS: We found patients with different Trp64Arg genotype showed significant differences in average uric acid concentrations (599.53±113.70 vs 529.78±81.10 vs 507.33±74.27, P<0.01) among CC, CT and TT genotype and there were significantly higher average uric acid concentrations in Trp64Arg TC+CC genotype individuals (557.95±99.91 vs 503.47±69.40 μmol/L, P<0.01) than those TT genotype subjects in the hyperuricemic group.CONCLUSION: Trp64Arg polymorphism was associated with hyperuricemia in a Chinese male population with type 2 diabetes mellitus.

Key words: Beta-3-adrenergic receptor, Genetic polymorphism, Hyperuricemia, Uric acid, Type 2 diabetes mellitus, Aassociation analysis

中图分类号:

R968

黄琼, 张留福, 程雁, 司力, 魏伟. β3肾上腺素受体基因Trp64Arg多态性与中国男性2型糖尿病患者合并高尿酸血症的相关性研究[J]. 中国临床药理学与治疗学, 2013, 18(3): 307-311.

HUANG Qiong, ZHANG Liu-fu, CHENG Yan, SI Li, WEI Wei. Effect of β3-adrenergic receptor gene Trp64Arg polymorphism on uric acid levels in a Chinese male type 2 diabetes mellitus population[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 307-311.

参考文献

[1] Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout[J]. Am J Manag Care, 2005, 11(15 Suppl): S459-464; quiz S65-68.
[2] Dalbeth N, Haskard DO. Mechanisms of inflammation in gout[J]. Rheumatology (Oxford), 2005, 44(9): 1090-1096.
[3] Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout[J]. Arthritis Res Ther, 2006, 8(Suppl 1): S2.
[4] Heinig M, Johnson RJ. Role of uric acid in hypertension, renal disease, and metabolic syndrome[J]. Cleve Clin J Med, 2006, 73(12): 1059-1064.
[5] Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes[J]. Diabetes Care, 2009, 32(9): 1737-1742.
[6] Nakanishi N, Okamoto M, Yoshida H, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers[J]. Eur J Epidemiol, 2003, 18(6): 523-530.
[7] Rho YH, Choi SJ, Lee YH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study[J]. J Korean Med Sci, 2005, 20(6): 1029-1033.
[8] Rho YH, Choi SJ, Lee YH, et al. The association between hyperuricemia and the Trp64Arg polymorphism of the beta-3 adrenergic receptor[J]. Rheumatol Int, 2007, 27(9): 835-839.
[9] Dehghan A, Kottgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study[J]. Lancet, 2008, 372(9654): 1953-1961.
[10] Yang Q, Guo CY, Cupples LA, et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study[J]. Metabolism, 2005, 54(11): 1435-1441.
[11] Conen D, Wietlisbach V, Bovet P, et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country[J]. BMC Public Health, 2004, 4: 9.
[12] Perfetti R, Hui H, Chamie K, et al. Pancreatic beta-cells expressing the Arg64 variant of the beta(3)-adrenergic receptor exhibit abnormal insulin secretory activity[J]. J Mol Endocrinol, 2001, 27(2): 133-144.
[13] Chamberlain PD, Jennings KH, Paul F, et al. The tissue distribution of the human beta3-adrenoceptor studied using a monoclonal antibody: direct evidence of the beta3-adrenoceptor in human adipose tissue, atrium and skeletal muscle[J]. Int J Obes Relat Metab Disord, 1999, 23(10): 1057-1065.
[14] Walston J, Silver K, Bogardus C, et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene[J]. N Engl J Med,1995, 333(6): 343-347.
[15] Widen E, Lehto M, Kanninen T, et al. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns[J]. N Engl J Med, 1995, 333(6): 348-351.
[16] Clement K, Vaisse C, Manning BS, et al. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity[J]. N Engl J Med, 1995, 333(6): 352-354.
[17] Chang HY, Pan WH, Yeh WT, et al. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96)[J]. J Rheumatol, 2001, 28(7): 1640-1646.
[18] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge[J]. Clin Chem, 1972, 18(6): 499-502.
[19] Doherty M. New insights into the epidemiology of gout[J]. Rheumatology (Oxford), 2009, 48 (Suppl 2): ii2-ii8.
[20] Roddy E, Zhang W, Doherty M. The changing epidemiology of gout[J]. Nat Clin Pract Rheumatol, 2007, 3(8): 443-449.
[21] Chuang SY, Lee SC, Hsieh YT, et al. Trends in hyperuricemia and gout prevalence: Nutrition and Health Survey in Taiwan from 1993-1996 to 2005-2008[J]. Asia Pac J Clin Nutr, 2011, 20(2): 301-308.
[22] Lin SD, Tsai DH, Hsu SR. Association between serum uric acid level and components of the metabolic syndrome[J]. J Chin Med Assoc, 2006, 69(11): 512-516.
[23] Coe FL, Evan A, Worcester E. Kidney stone disease[J]. J Clin Invest, 2005, 115(10): 2598-2608.
[24] Bea JW, Lohman TG, Cussler EC, et al. Lifestyle modifies the relationship between body composition and adrenergic receptor genetic polymorphisms, ADRB2, ADRB3 and ADRA2B: a secondary analysis of a randomized controlled trial of physical activity among postmenopausal women[J]. Behav Genet, 2010, 40(5): 649-659.